Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Product Briefs

This article was originally published in The Gray Sheet

Executive Summary

Hologic: Company expects to launch its new radiation therapy system by the end of the year, having secured FDA clearance Aug. 27, Hologic announced Sept. 1. MammoSite ML is a multi-lumen version of the firm's original, single-lumen MammoSite system, cleared in 2002. The accelerated partial breast irradiation (APBI) devices provide targeted breast cancer radiation therapy directly to the area where cancer is most likely to recur by inflating a balloon catheter containing radioactive material into the surgical cavity after the tumor is removed. The multi-lumen model allows oncologists to shift the radiation dose to the areas within the cavity that need it most, the firm explains. Hologic obtained the MammoSite technology when it bought Cytyc for $6.2 billion in 2007 (1"The Gray Sheet" May 28, 2007)

You may also be interested in...



St. Jude Brings Remote Monitoring System To Pacemakers

St. Jude Medical's Merlin.net Patient Care Network monitoring system now supports all three types of cardiac rhythm management devices, following FDA approval of St. Jude's Accent RF pacemaker and Anthem RF cardiacresynchronization therapy pacemaker (CRT-P)

Hologic/Cytyc Merger Combines Diverse Women’s Health Device Portfolios

The combination of mammography device maker Hologic and cervical cancer test firm Cytyc will create a women's health powerhouse with $1.44 billion in combined annual revenues

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: landmark results for lecanemab in Alzheimer’s; other Alzheimer’s players rise after the lecanemab results; Leqvio’s importance to Novartis; Pfizer’s secret sauce for digitalization; and Amgen’s clinical trial diversity efforts.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT027883

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel